Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pemphigus Vulgaris - Overview
Pemphigus Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pemphigus Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pemphigus Vulgaris - Companies Involved in Therapeutics Development
Argenx SE
Biogen Inc
BioXpress Therapeutics SA
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
Hall Biopharma Co Ltd
iBio Inc
Octagon Therapeutics Inc
Pharmapraxis
Topas Therapeutics GmbH
Pemphigus Vulgaris - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-212525 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target DSG1 and DSG3 for Mucocutaneous Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target DSG3 for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OW-177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPM-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pemphigus Vulgaris - Dormant Projects
Pemphigus Vulgaris - Discontinued Products
Pemphigus Vulgaris - Product Development Milestones
Featured News & Press Releases
Aug 18, 2021: Cabaletta Bio reports clinical data from the second dose cohort in DesCAARTes trial in patients with mPV
May 03, 2021: Cabaletta Bio reports acute safety data from the first dose cohort in DesCAARTes trial
Dec 08, 2020: Cabaletta Bio announces first patient dosed in Landmark DesCAARTes trial of DSG3-CAART for treatment of mucosal-domint pemphigus vulgaris
Aug 25, 2020: Cabaletta Bio announces publication of comprehensive preclinical study results for DSG3-CAART in pemphigus vulgaris
May 06, 2020: Cabaletta Bio receives FDA Fast Track Desigtion for DSG3-CAART for the treatment of Mucosal Pemphigus Vulgaris
Jan 29, 2020: FDA grants DSG3-CAART orphan drug desigtion for the treatment of pemphigus vulgaris
Dec 18, 2019: Topas Therapeutics announces first patient enrolled in phase 1 trial with TPM203 in pemphigus vulgaris
Oct 14, 2019: Roche’s Rituxan outperforms MMF in pemphigus vulgaris study
Oct 01, 2019: Cabaletta Bio receives IND clearance from FDA to initiate first clinical trial of DSG3-CAART in patients with Mucosal Pemphigus Vulgaris
Jun 12, 2019: Phase III PEMPHIX study showed that Genentech’s Rituxan (Rituximab) is superior to standard of care in achieving sustained remission in patients with Pemphigus Vulgaris
Mar 15, 2019: EC approves Roche’s MabThera for pemphigus vulgaris
Jan 31, 2019: CHMP recommended extension of indication for Mabthera
Dec 12, 2018: Cell therapy industry pioneer, Gwendolyn Binder, Ph.D., to join Cabaletta Bio leadership team
Jul 24, 2018: argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Jourl of Clinical Investigation
Jun 20, 2018: argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Pemphigus Vulgaris, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Pemphigus Vulgaris, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pemphigus Vulgaris - Pipeline by Argenx SE, 2021
Pemphigus Vulgaris - Pipeline by Biogen Inc, 2021
Pemphigus Vulgaris - Pipeline by BioXpress Therapeutics SA, 2021
Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, 2021
Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, 2021
Pemphigus Vulgaris - Pipeline by iBio Inc, 2021
Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, 2021
Pemphigus Vulgaris - Pipeline by Pharmapraxis, 2021
Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, 2021
Pemphigus Vulgaris - Dormant Projects, 2021
Pemphigus Vulgaris - Discontinued Products, 2021